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at baseline compared to the NSAID group. After adjusting for
these factors, no signiﬁcant differences were observed in the rate
of GI events (1% overall), rate of GI medication use (5%) total
health care costs (mean = $1712), or medical costs (mean =
$1513) after 1 year. Prescription drug costs were 38% and 51%
higher for rofecoxib and celecoxib patients respectively com-
pared to the NSAID group (p < 0.0001). CONCLUSION: In
contrast to initial marketing information, in this observational
study, we found no signiﬁcant difference in GI-related outcomes
or total health care costs between the two groups.
PAR7
HEALTH CARE UTILIZATION AND EXPENDITURE OF TWO
PROGRAMS FOR OSTEOARTHRITIS OF THE KNEE AND HIP:
ASSESSMENT AND IMPACT IN REAL-LIFE CONDITIONS
De Jong R1, Hopman-Rock M2,Tak E1, Klazinga N3
1TNO Quality of Life, Leiden,The Netherlands; 2TNO Quality of
Life/TNO-VU University Medical Center Amsterdam, Leiden,The
Netherlands; 3University Medical Centre, Amsterdam,The
Netherlands
OBJECTIVE: To assess in real-life conditions after previous ran-
domized controlled trials the impact on health care utilization
and expenditure of two self-management programs for older
adults with osteoarthritis (OA) of the knee and hip. METHODS:
Eighteen primary health-care providers were recruited to carry
out a Knee or Hip program. Study participants were older adults
(>55 years) with diagnosed OA of knee or hip. Self-reported data
were collected with pre-test/post-test questionnaires (consulta-
tion of the general practitioner, physiotherapeutic treatment,
consultation of the medical specialist, and use of OA medica-
tion). Pre-test/post-test data of four health insurance companies
were collected on expenditure for physiotherapy and OA med-
ication. RESULTS: Providers delivered 20 Knee and 20 Hip pro-
grams. Background variables of program participants were
comparable with background variables in the RCTs. Signiﬁcant
fewer participants of the Knee program (n = 157) reported
receiving physiotherapy after completion of the program (P =
0.00). In the Hip program (n = 132), the self-reported frequency
of visits to physiotherapists (P = 0.00) and medical specialists (P
= 0.03) decreased. The self-reported use of OA medication had
decreased in both programs (P = 0.00). No effect was observed
for consultations of the general practitioner. The outcomes were
comparable with the outcomes of the RCTs. Expenditure for
physiotherapy and OA medication could not be assessed, due to
difﬁculties in obtaining sufﬁcient reliable data. Expenditure were
not measured in the RCTs. CONCLUSION: Considering the
limitations of the study, both programs indicate ecological valid-
ity as to health care utilization. Compared to the RCTs, the pro-
grams produced similar outcomes in real-life conditions. The
combination of the self-reported reduction in the use of physio-
therapy and the self-reported reduction in the use of OA med-
ication indicate also improved OA symptom control. A guideline
for accurate data collection on OA expenditure is recommended.
Cost-utility and cost-effectiveness analysis is recommended, once
large-scale dissemination in the primary health care system is
realized.
PAR8
COST COMPARISON OF THE COMBINATION TRAMADOL
PLUS PARACETAMOL VERSUS NSAIDS PLUS PROTON PUMP
INHIBITORS IN THE TREATMENT OF OSTEOARTHRITIS IN
THE NETHERLANDS
Liedgens H1, Nuijten MJ2, Poulsen Nautrup B1
1Gruenenthal GmbH, Aachen, Germany; 2Erasmus University,
Rotterdam,The Netherlands
OBJECTIVES: Non-steroidal anti-inﬂammatory drugs (NSAIDs)
are often used as ﬁrst-line treatment in osteoarthritis (OA). Due
to the increased risk of gastrointestinal (GI) side effects with
NSAIDs, proton pump inhibitors (PPIs) are often prescribed con-
comitantly, but cannot entirely prevent these complications.
Since the combination of the weak opioid tramadol plus parac-
etamol has shown to be an alternative treatment in OA we aimed
to compare the costs of six months’ treatment of OA with
NSAIDs plus PPIs with the tramadol/paracetamol combination
(Zaldiar®) in the Dutch health care setting. METHODS: A cost
comparison of the direct medical costs was appropriate since
both treatments have been shown to be similarly efﬁcacious in
treatment of OA pain of comparable intensity. We combined the
Celecoxib Outcomes Measurement Tool (COMET) for evalua-
tion of cost consequences of NSAIDs plus PPIs with a modiﬁed
model for cost consequences of the tramadol/paracetamol com-
bination presented previously. The NSAIDs under study were
diclofenac and ibuprofen and the PPIs were omeprazole and pan-
toprazole, representing 75% and 85% of the respective market
shares (by units) in The Netherlands. Probabilities were derived
from published literature. Resource utilization data were
obtained from published literature, Delphi panel and ofﬁcial
price and tariff lists (Dutch costing manual). The perspective
taken was that of the health insurance. RESULTS: Costs of six
months’ treatment of OA pain with the tramadol/paracetamol
combinations were €244.45. Savings compared with NSAIDs
plus PPIs treatment were €72.87. Taking into account the rare,
but very cost-consuming, renal side effects of NSAIDs, savings
were €414.79 for six months’ treatment (costs of NSAIDs plus
PPI treatment: €317.32, including renal side effects: €659.24).
Sensitivity analyses conﬁrmed the robustness of the model.
CONCLUSION: The tramadol/paracetamol combination offers
a cost-saving alternative treatment of OA that is not associated
with severe GI or renal complications.
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OBJECTIVE: To develop a model to translate WOMAC scores
collected in clinical trials of patients with osteoarthritis (OA) into
Health Utilities Index Mark 3 (HUI3) utility scores for applica-
tion in economic evaluation. METHODS: Data from a previ-
ously published open-label randomized controlled trial of
appropriate care with hylan G-F 20 vs. appropriate care without
hylan G-F 20 in 255 outpatients with knee OA. We estimated
linear regression models of HUI3 scores using various functions
of WOMAC, demographics and clinical variables. Out of sample
predictive performance of the models was assessed using the
mean absolute error and several other criteria. RESULTS: The
preferred model included WOMAC pain, stiffness, function sub-
scales, and demographic variables; it accounted for almost 40%
of the variation in the HUI3 utility scores. At the group level,
absolute differences between predicted and actual overall HUI3
utility scores was <0.001 and not statistically signiﬁcantly dif-
ferent from zero. CONCLUSION: A model appropriate for ret-
rospective analyses of data sets in which utility scores were not
collected was developed to estimate HUI3 scores from WOMAC
A27Abstracts
scores for application in OA. Researchers can estimate overall
utility scores, compute QALYs, and perform cost-utility analy-
ses within a deﬁned range of uncertainty.
PAR10
ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE
INTERNATIONAL CLASSIFICATION OF FUNCTIONING,
DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS
FROM THE PERSPECTIVE OF PATIENTS WITH KNEE
OSTEOARTHRITIS IN SINGAPORE
Xie F1,Thumboo J2, Fong KY2, Lo NN2,Yeo SJ2,Yang KY2, Li SC1
1National University of Singapore, Singapore, Singapore, Singapore;
2Singapore General Hospital, Singapore, Singapore, Singapore
OBJECTIVES: To determine the extent to which health items
identiﬁed from the perspective of patients with knee osteoarthri-
tis can be linked with the ICF; and to critically evaluate the 
ICF Comprehensive and Brief Core Sets for osteoarthritis.
METHODS: Items identiﬁed from a focus group study were
linked independently by two researchers based on the 10 a priori
linking rules. Both percentage agreement and kappa statistics
were calculated to measure inter-observer agreement. Any dis-
agreements were resolved by reaching a consensus among the
researchers. The categories linked with all items were compared
with the Comprehensive Core Set for osteoarthritis, while the
categories linked with those items reported as important by over
30% of subjects within each of 3 local ethnic groups (i.e.
Chinese, Malay, and Indian) were compared with the Brief Core
Set. Both comparisons were made only at the second level of the
ICF. RESULTS: Totally 74 items were linked with 44 different
ICF categories through 105 linkages with generally very good
inter-observer agreement. The 69 items were linked with the ICF
at the third or fourth levels. Both commonalities and disparities
were found through comparison between the categories linked
with these items and both Core Sets for osteoarthritis. CON-
CLUSIONS: In this study, all items could be successfully linked
with the ICF. The ICF Comprehensive Core Set demonstrated
general conceptual validity, while the Brief Core Set needs to be
supported by more empirical evidence in various socio-cultural
contexts. This study speciﬁcally complemented the development
and reﬁnement of both Core Sets from the perspective of patients
with knee osteoarthritis.
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OBJECTIVE: The 18-item ARTS questionnaire measures 4
dimensions relative to satisfaction with osteoarthritis treatment:
Effectiveness, Convenience, Tolerability, and Medical Care.
Validity studies and discriminant properties are reported in order
to establish a clinical relevant difference in the overall score and
a satisfaction threshold. METHODS: Two samples are com-
pared: a normative group of 163 used for linguistic validation
and an unsatisﬁed group of 1750 patients derived to a more tol-
erated treatment with COX-2. Groups are compared using t-test,
ANOVA and Tukey’s HSD. Sensitivity and related ﬁgures are
estimated using the ROC curve using as criteria the patients’
need of change in treatment (judged by the clinician). RESULTS:
The normative group renders a normal distribution of scores
(65.4 + 13.4, mean + SD), slightly biased above the 0–100 scaled
mid-point. The total score mean value for the unsatisﬁed sample
(52.5 + 11.1) was signiﬁcantly lower (p < 0.001) than for the
normative group, and much lower than the satisﬁed subgroup
(76.5 + 13.9). By dimensions, the larger difference between the
satisﬁed subgroup and the rest of patients who needed change
was observed in the Effectiveness dimension (dif = 34.1, t =
11.3), followed by Convenience (dif = 27.3, t = 10.1), Tolera-
bility (dif = 26.5, t = 5.3), and Medical Care (dif = 14.0, t = 5.7).
No differences were found between genders, neither in the nor-
mative group nor in the unsatisﬁed group. Sensitivity = 72%,
speciﬁcity = 77%, positive predictive value = 89% and negative
predictive value = 53% are obtained using a cut-off point of
69.18 determined from the clinical judgment of a need of change
in treatment (threshold value). Signiﬁcance differences in mean
score are also found between groups differing in tolerance to
actual treatment. CONCLUSION: ARTS is a sensitive instru-
ment and can be used to detect differences in the patients’ satis-
faction with osteoarthritis treatment. Differences between
groups of known satisfaction level are signiﬁcant and meaning-
ful, although it should be noted that the normative mean score
is above the scale midpoint.
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OBJECTIVES: To estimate change in quality of life (QoL) in
patients with psoriatic arthritis (PsA) receiving adalimumab vs.
placebo, as measured by the health utility measurement Short
Form 6D (SF-6D). METHODS: In a placebo-controlled, Phase
III trial of adalimumab (ADEPT), patients with active PsA
received adalimumab 40mg every other week (eow) or placebo
for 24 weeks. The SF-6D was estimated at baseline, 12 weeks
and 24 weeks using responses to the Short Form 36 (SF-36)
patient questionnaire. Multiple linear regression models were
estimated to explore the effects of age, sex, disease duration, con-
comitant therapies, baseline Health Assessment Questionnaire
Disability Index (HAQ DI), and the Psoriasis Area and Severity
Index (PASI). Patients were further differentiated as responders
or non-responders using the Psoriatic Arthritis Response Crite-
ria (PsARC) and an improvement in the PASI by 75% (PASI 75).
RESULTS: Baseline SF-6D values were 0.66 and 0.65 for the
adalimumab and placebo arms respectively. Overall, adali-
mumab improved health utility by 10.6% (SD = 18.9) in com-
parison to 2.9% (SD = 16.2) for placebo. Adalimumab was
particularly efﬁcacious in patients with skin involvement (13.7%
(SD = 20.9) versus 0.5% (SD = 17.0)). PsARC response was a
signiﬁcant predictor of utility improvement, and, for patients
with skin involvement, PASI 75 was also important CONCLU-
SIONS: These ﬁndings demonstrate that adalimumab was efﬁ-
cacious in improving PsA patients’ quality of life; and this
efﬁcacy was observed to an even higher degree in patients with
more skin involvement. Health utilities, when modeled with
associated costs over a patients’ lifetime, will facilitate the eco-
nomic evaluations of adalimumab.
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